Business Wire

DE-CSC

9.10.2019 14:02:11 CEST | Business Wire | Press release

Share
CSC Introduces New Domain Name Security Intelligence API at the Cyber Defense Summit 2019 Hosted by FireEye

CSC announces a new domain name security intelligence API that can now bring together the power of CSC’s domain name security intelligence with other cloud-based security operations platforms. Debuting today at the FireEye Cyber Defense Summit 2019, this new solution will help the world's leading security experts, government leaders, and executives from various industries address important challenges in today’s cyber threat landscape, including the vulnerability of digital assets like domains, domain name systems (DNS), and digital certificates outside the firewall, noted by both companies as serious security blind spots.

Cyber threats such as domain name and DNS hijacking events enable criminals to redirect web traffic, email, apps, and other connections to services that rely on the hijacked domain name. The exploitation of weaknesses in DNS infrastructure is caused by a lack of controls, processes, and policies with most organizations. For clients leveraging a security operations platform or a SIEM, it’s now possible to display all your security intelligence in one place, adding security controls for domains, DNS, and digital certificates. This insight can help organizations mitigate the disruption of business continuity, leading to financial repercussions, loss of consumer trust, and sensitive data leaks. This is the first time any organization is able to integrate security controls for digital assets outside the firewall into their security operations platform including a SIEM.

“Customers today have vendor fatigue and are overwhelmed by managing multiple, disparate security solutions. With the CSC API accessible, our mutual customers will be able to monitor a suite of security events that occur outside their company’s firewall when integrated with the FireEye Helix Security Platform,” says Sean Morton, vice president of Customer Experience at FireEye. “Detecting risks such as DNS and domain name hijacking removes a significant blind spot in a company’s security strategy, providing valuable intelligence and alerts inside our security operations platform, ultimately increasing the efficiency and incident response times dealing with cyber threats.”

“As the world’s leading corporate domain name registrar, CSC is the only company in the unique position to provide visibility into the cyber risks associated with your business-critical digital assets outside the firewall—domains, DNS, and digital certificates. Coupled with other security operations platforms like FireEye Helix, our joint customers have access to a next generation security platform,” says Mark Calandra, senior vice president, CSC Digital Brand Services. “In response to the risk of DNS hijacking and other cyber crime noted in the Department of Homeland Security’s emergency directive and the UK National Cyber Security Centre’s security advisory , CSC’s advanced proprietary algorithms are designed to expose these blind spots that are a critical component for enhancing the security posture of any company with an online presence.”

The Cyber Defense Summit is being hosted by FireEye, and the conference takes place October 9-10, 2019, in Washington, D.C. CSC representatives will be in the exhibition hall to discuss CSC’s new Domain Name Security Intelligence API and its integration with FireEye Helix. We will also be discussing our recent Cyber Security Report highlighting the domain name security posture of global government defense contractors.

About CSC

CSC supports companies that are making significant investments in their security posture by exposing blind spots that exist within fundamental internet assets such as domain names, DNS, and digital certificates. By leveraging our proprietary security solutions, CSC secures companies from cyber threats to their digital assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties as a result of policies like GDPR. Along with internet assets, CSC protects online brands that are being exploited via counterfeit websites, fraud, and IP violations, and helps monitor and mitigate this, providing enforcement and advisory services to protect many of the world’s largest brands. Learn more at cscdigitalbrand.services .

About FireEye, Inc.

FireEye is the intelligence-led security company. Working as a seamless, scalable extension of customer security operations, FireEye offers a single platform that blends innovative security technologies, nation-state grade threat intelligence, and world-renowned Mandiant® consulting. With this approach, FireEye eliminates the complexity and burden of cyber security for organizations struggling to prepare for, prevent, and respond to cyber-attacks. FireEye has over 8,200 customers across 103 countries, including more than 50 percent of the Forbes Global 2000.

Link:

ClickThru

Social Media:

https://www.facebook.com/CSCSince1899/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye